Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2–6 years in Germany
Falkenhorst, G.; Harder, T.; Remschmidt, C.; Terhardt, M.; Zepp, F.; Ledig, T.; Wicker, S.; Keller-Stanislawski, B.; Mertens, T. · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · 2013 · Heft 10 · S. 1557 bis 1564
Bibliografische Angaben
Zusammenfassung
The German Standing Committee on Vaccination (STIKO) recommends seasonal influenza vaccination for children and adolescents with chronic medical conditions that put them at risk for severe influenza illness. In addition to trivalent inactivated influenza vaccines (TIV), a trivalent live-attenuated influenza vaccine (LAIV) was licensed for children and adolescents aged 2–17 years in the European Union in 2011. Employing the methodology of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group, we examined the evidence for efficacy and safety of LAIV relative to TIV to guide ST…
